Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Test And Treat In Washington, DC: Evaluating The Costs And Benefits Of A Comprehensive Strategy To Fight HIV/AIDS

E. Raimondo
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
This paper assesses the economic implications of an innovative approach to preventing the spread of HIV/AIDS in Washington, DC. “Test & Treat” is premised on the idea that the epidemic can ultimately be eliminated by testing people widely and regularly and by putting all infected persons on antiretroviral medicines upon diagnosis. The relative costs and benefits of Test & Treat are quantified, monetized, and compared to the status quo, which can be characterized as a ‘test and wait’ approach. This cost-benefit analysis concludes that under a plausible set of circumstances, and with a conservative estimate of the number of infections averted, the benefits of Test & Treat in Washington, DC would outweigh the costs of implementation.
This paper references
Variations between Countries in Values of Statistical Life
T. Miller (2000)
Failure to establish HIV care: characterizing the "no show" phenomenon.
M. Mugavero (2007)
The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States
B. Schackman (2006)
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC.
R. Walensky (2010)
What Determines the Value of Life: A Meta‐Analysis
J. Mrozek (2002)
linkage-to-Care and ArT Adherence Practices at Participating Sides in the hPTN 065 (TlC-Plus) Study.
E. Greene (2012)
Expanded Antiretroviral Therapy in New york City: Modeling the impact.” Presentation at the Conference on retroviruses and opportunistic infections
Kessler (2012)
"Test and treat": is it enough?
J. Lange (2011)
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.
E. Gardner (2011)
Comparative effectiveness of HIV testing and treatment in highly endemic regions.
E. Bendavid (2010)
Clinical Infectious Diseases 51(4):392-400
DC Washington (2010)
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
R. Granich (2009)
Human immunodeficiency virus counseling, testing, referral, and partner notification services. A cost-benefit analysis.
D. Holtgrave (1993)
To test or not to test: psychosocial barriers to HIV testing in high‐income countries
J. D. de Wit (2008)
The hiv/AiD Epidemic in Washington, DC” Last modified July 2012
Kaiser Family Foundation. (2012)
Cost-Benefit Analysis: Concepts and Practice
A. Boardman (1996)
Clinical Infectious Disease: Clinical Syndromes – Respiratory Tract
D. Schlossberg (2008)
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
J. Montaner (2010)
CostBenefit Analysis, Concepts and Practice, 4th edition
Boardman (2011)
Cost-effectiveness of HIV testing and treatment in the United States.
R. Walensky (2007)
Guidelines for the Use of Antiretroviral Agents in hiv1infected Adults and Adolescents
J. B. F. De Wit
Worry: Women’s Experience of HIV Testing
Jane Ransom (2005)
The lifetime Cost of Current
Moore (2006)
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000
A. Fauci (2000)
Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.
B. Branson (2006)
Coming to terms with complexity: a call to action for HIV prevention
P. Piot (2008)
Barriers and pathways to testing among HIV-infected women.
K. Siegel (1998)
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis
Suzanna Attia (2009)

Semantic Scholar Logo Some data provided by SemanticScholar